Standard BioTools Inc. (LAB) AI Stock Analysis

Standard BioTools Inc. develops, manufactures, and distributes advanced instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. Its analytical platforms include the Helios CyTOF system, Hyperion imaging systems, Hyperion tissue imagers, and flow conductors. The company provides Maxpar assays and reagents, including direct immune profiling assays and IMC panel kits for immuno-oncology. In addition, it supplies preparatory instruments such as Juno, Biomark HD, and EP1 systems, alongside integrated fluidic circuits and C1 systems for single-cell analysis. Formerly known as Fluidigm Corporation, the company rebranded in April 2022 and works under strategic license agreements with institutions including the California Institute of Technology and Harvard University.

Revenue fell 51.1% in FY2025 to $85.3M from $174.4M in FY2024, following a 5-year revenue CAGR of -9.2% from FY2020 to FY2025. Gross margin was 49.9% in FY2025, while operating margin was -109.3%. Net income remained negative at -$74.9M, representing an EPS of -$0.06. In the latest quarter ended June 30, 2026, revenue declined 7.6% year-over-year, bringing trailing twelve-month revenue to $84.6M. Operating margin over the trailing twelve months stood at -38.9%, with an EPS of -$0.13, while net profit margin was 100.4%.

As of June 30, 2026, Standard BioTools held $476.7M in cash and short-term investments and $28.1M in total debt, resulting in net cash of $448.6M. Shareholders' equity was $540.0M, supporting a debt-to-equity ratio of 0.05 and a current ratio of 9.10. Cash flow remained constrained, as free cash flow was -$82.7M in FY2025 on operating cash flow of -$74.3M. In FY2025, capital expenditures were $8.3M and share issuance generated $1.1M, while the share count expanded by 409.9% over five years.

Standard BioTools trades at a price-to-sales multiple of 2.9x, below the 4.1x median of its US-listed Healthcare peers. Its price-to-book ratio is 0.5x, and its enterprise value is -$170.3M, resulting in an EV-to-revenue ratio of 0.3x. Market capitalization sits at $246.9M at a share price of $0.63 as of October 16, 2026. The stock declined 51.2% over the prior year and 88.2% over five years, underperforming the S&P 500 (SPY), which gained 16.8% and 83.0% across those respective periods.

Wall Street coverage tracked shows 1 Hold rating, with no Strong Buy, Buy, Sell, or Strong Sell ratings. The mean price target is $1.35, representing a 114.3% upside from the last close of $0.63. For the fiscal year ending December 31, 2026, the EPS estimate is -$0.10 on projected revenue of $82.5M. For the next fiscal year, the single covering analyst projects an EPS of -$0.16 on revenue of $82.1M. The company beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 3, 2026.

This page is an AI-written research summary of Standard BioTools Inc. (LAB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: LAB income statement, LAB balance sheet, LAB key metrics, LAB analyst forecast, LAB chart. See the LAB stock overview for the latest quote and news.